Core Viewpoint - The announcement details the completion of Phase I clinical trials for ZG-002, a novel drug developed by Shanghai Zhigen Pharmaceutical Technology Co., Ltd., which is a subsidiary of Hunan Warner Pharmaceutical Co., Ltd. The drug is aimed at treating moderate to severe plaque psoriasis and has shown promising safety and efficacy results in preliminary studies [1][2]. Drug Overview - ZG-002 is a first-in-class new drug designed to treat autoimmune diseases, specifically targeting moderate to severe plaque psoriasis [1]. - It is characterized as a potent and highly selective TYK2 allosteric inhibitor, demonstrating superior TYK2 inhibition and efficacy in animal models of psoriasis [2]. Phase I Clinical Trial Results - The primary objective of the Phase I clinical trial was to assess the safety, tolerability, pharmacokinetics, and food effects of ZG-002 in healthy adult subjects [3]. - Results indicated good safety and tolerability, with no serious adverse events reported. Adverse events related to the drug were mild (Grade 1 or 2) and transient [4]. - Pharmacokinetic data showed a clear relationship between drug exposure and dosage, with no significant gender differences observed. High-fat meals delayed peak concentration but did not significantly affect overall exposure [4]. Efficacy Indicators - Pharmacodynamic analysis revealed that IFN-γ levels decreased with increased drug exposure, suggesting potential therapeutic effects for moderate to severe psoriasis. The exposure-effect curve indicated a plateau effect at doses of 16mg QD and above [4][5]. - The current dosing regimen shows good safety and pharmacokinetic characteristics, supporting further exploratory clinical studies in patient populations [5].

Core Viewpoint - Warner Pharmaceuticals (688799.SH) announced that its associate company, Shanghai Zhigen Pharmaceutical Technology Co., Ltd. (referred to as "Zhigen Pharmaceutical"), has completed Phase I clinical trials for its independently developed drug ZG-002 under the approval of the National Medical Products Administration [1] Group 1: Drug Development - ZG-002 is a novel drug with a new structure aimed at treating moderate to severe plaque psoriasis, classified as a Class 1 new drug [1] - The primary objective of the clinical trial was to evaluate the safety, tolerability, pharmacokinetic characteristics, and food effects of ZG-002 in healthy adult subjects [1] - The current dosing regimen of ZG-002 has shown good safety and tolerability, with clear pharmacokinetic characteristics [1] Group 2: Future Research - The clinical data obtained from this study supports the further exploration of additional clinical research in patient populations [1]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) announced that its affiliate, Shanghai Zhigun Pharmaceutical Technology Co., Ltd., has completed Phase I clinical trials for ZG-002, a novel drug for autoimmune diseases, with the approval of the National Medical Products Administration [1] Group 1: Drug Development - ZG-002 is a first-class new drug developed by Zhigun Pharmaceutical, specifically targeting moderate to severe plaque psoriasis [1] - Preclinical studies indicate that ZG-002 is a potent and highly selective TYK2 allosteric inhibitor, demonstrating superior TYK2 inhibition activity and selectivity in vitro [1] - In classic animal models of psoriasis, ZG-002 has shown promising therapeutic effects, indicating its potential as a new generation of safer and more effective psoriasis treatment [1] Group 2: Safety and Efficacy - ZG-002 exhibits excellent metabolic properties and safety alongside its strong in vitro and in vivo activity [1] - The research results suggest that ZG-002 has the potential to expand its clinical applications to other autoimmune diseases [1]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) announced that its associate company, Shanghai Zhigen Pharmaceutical Technology Co., Ltd., has completed Phase I clinical trials for ZG-002, a novel drug for autoimmune diseases, with the approval of the National Medical Products Administration [1] Group 1: Clinical Trial Details - ZG-002 is a first-in-class new drug developed by Zhigen Pharmaceutical, currently intended for the treatment of moderate to severe plaque psoriasis [1] - The primary objective of the clinical trial was to evaluate the safety, tolerability, pharmacokinetics, and food effects of ZG-002 in healthy adult subjects [1] - The trial results indicate that ZG-002 has good safety and tolerability under the current dosing regimen, with clear pharmacokinetic characteristics [1] Group 2: Future Research Implications - The clinical data obtained from this study supports the further exploration of ZG-002 in subsequent clinical research involving patient populations [1]